Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Co-Diagnostics's share price for the quarter that ended in Mar. 2025 was $0.3096. Co-Diagnostics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 33.57 Mil. Therefore, Co-Diagnostics's market cap for the quarter that ended in Mar. 2025 was $10.39 Mil.
Co-Diagnostics's quarterly market cap
declined
from Sep. 2024 ($39.91 Mil) to Dec. 2024 ($24.79 Mil) and
declined
from Dec. 2024 ($24.79 Mil) to Mar. 2025 ($10.39 Mil).
Co-Diagnostics's annual market cap
declined
from Dec. 2022 ($77.80 Mil) to Dec. 2023 ($41.58 Mil) and
declined
from Dec. 2023 ($41.58 Mil) to Dec. 2024 ($24.79 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Co-Diagnostics's Enterprise Value for Today is $-10.61 Mil.
Co-Diagnostics Market Cap Historical Data
The historical data trend for Co-Diagnostics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Co-Diagnostics's Market Cap
For the Medical Devices subindustry, Co-Diagnostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Market Cap distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Co-Diagnostics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (NAS:CODX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Co-Diagnostics Market Cap Related Terms
Thank you for viewing the detailed overview of Co-Diagnostics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CODX has been successfully added to your 